Active Ingredient(s): Pertuzumab + Trastuzumab + Hyaluronidase-zzxf
FDA Approved: * June 29, 2020
Pharm Company: * GENENTECH INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Phesgo Overview

Pertuzumab/trastuzumab/hyaluronidase, sold under the brand name Phesgo, is a fixed-dose combination medication to treat adults with HER2-positive breast cancer that has spread to other parts of the body, and for treatment of adults with early HER2-positive breast cancer.[3] It contains pertuzumab, trastuzumab, and hyaluronidase–zzxf.[3] It is injected under the skin via subcutaneous injection in the thigh.[3] In the European Union, Phesgo ...

Read more Phesgo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Phesgo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Pertuzumab + Trastuzumab + Hyaluronidase-zzxf
  • Injection: 1,200mg + 600mg + 30,000units, 1200mg + 600mg + 30000units, 600mg + 600mg + 20,000units
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Phesgo: (2 results)

Sorted by National Drug Code
  • 50242-245 Phesgo Subcutaneous Injection, Solution by Genentech, Inc.
  • 50242-260 Phesgo Subcutaneous Injection, Solution by Genentech, Inc.

Drugs with one or more similar ingredients: (16 results)